Wegovy Age Limit and Seniors: What the Licence Actually Says

Is there a Wegovy age limit that rules seniors out?

The short answer is no. The MHRA-approved licence for Wegovy, as detailed on the NHS semaglutide medicines page, draws a line at the bottom of the age range (it is not licensed for anyone under 18) but sets no ceiling. Our Wegovy age limit guidance explains that a person in their 60s, 70s or beyond can be prescribed Wegovy in the UK provided they meet the clinical criteria and a prescriber judges the benefits to outweigh the risks for them specifically.

What this means in practice is that age becomes one piece of information in a broader clinical picture, rather than a pass-or-fail gate. NICE's recommendation for semaglutide (sited in technology appraisal TA875) sets out eligibility around BMI and weight-related comorbidities, not birth year. Prescribers working within those guidelines consider the whole person: other medicines being taken, organ function, nutritional status, and what the patient is trying to achieve.

If you have been turned away elsewhere because of your age without a proper clinical discussion, our dedicated page on Wegovy age considerations is a good place to understand what a proper eligibility review should involve. Age alone is not a clinical reason to decline treatment.

What prescribers look at more carefully in older patients

Older adults are more likely to be taking several medicines at once, and semaglutide slows gastric emptying, which can affect how quickly some tablets are absorbed. Prescribers pay attention to any medicines that are time-sensitive or have a narrow therapeutic window. This is not a contraindication, but it is a conversation worth having.

Kidney function tends to decline gradually with age. Severe dehydration caused by vomiting or diarrhoea (possible in the early weeks of treatment) can put additional strain on kidneys that are already working less efficiently. Staying well hydrated matters for everyone on Wegovy, and for older patients it is especially worth monitoring. Cardiovascular history also comes into play: Wegovy holds a separate UK authorisation for reducing major cardiovascular event risk in eligible adults, so for some older patients with established heart disease the medicine may be indicated on more than one ground.

None of these factors are unique to seniors, but they tend to cluster in older age. A prescriber working through your application (which you can read more about on our Wegovy overview page) will weigh all of them before approving treatment.

The muscle-loss question and why it matters more as you get older

This is the concern our prescribers hear most often from patients in their 60s and 70s: will Wegovy eat into muscle as well as fat? It is a fair question. Semaglutide reduces appetite significantly, and if that translates into eating too little protein, lean tissue can be lost alongside body fat, a pattern called sarcopenia that accelerates naturally from around the age of 60.

Clinical guidance consistently points to two protective factors: adequate protein at every meal (roughly 25–30 grams per sitting helps stimulate muscle synthesis), and resistance or weight-bearing activity. These are not optional extras for older patients on Wegovy; they are part of how the treatment is supposed to work. For context on how Wegovy fits into a broader weight-management approach, the weight-loss treatment overview covers the lifestyle element alongside the medicine.

The gastrointestinal side effects most people experience in the first weeks of treatment (nausea, reduced appetite, occasional vomiting) can make eating enough protein feel difficult. Our Wegovy for seniors page covers how starting on the lowest dose and titrating slowly under prescriber guidance gives the body time to adjust. If you are finding it hard to eat enough, that is a clinical matter to raise with your prescriber rather than something to manage quietly.

Deciding whether to pursue a private prescription

If you are weighing up whether to seek a private Wegovy prescription, the honest framing is this: a legitimate service will never approve you on age criteria alone, in either direction. What it will do is give your health picture a thorough review by a qualified prescriber. At nume, every consultation is read by a GPhC-registered Independent Prescriber, a real clinician who looks at your submitted information the same day.

It is worth knowing that treatment cost is sometimes a concern for people on fixed incomes. Our Wegovy pricing page explains what is included in a private prescription from a registered pharmacy, so you can make a fully informed decision before starting a consultation.

For broader context on what the semaglutide licence covers and how it applies across different patient groups, our semaglutide age guidance page is a useful companion to understanding how eligibility works across different life stages. And if you are still working out which treatment might suit your situation, starting a free consultation is how our prescribers get to know yours.